Akebia Therapeutics (AKBA) Equity Ratio (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Equity Ratio data on file, last reported at 0.08 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.08, down 4.71% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.08 (down 4.71% YoY), and the FY2025 annual result was 0.09, up 138.85% from the prior year.
• Equity Ratio eased to 0.08 in Q1 2026 per AKBA's latest filing, from 0.09 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.11 in Q3 2025 and troughed at 0.24 in Q3 2024.
• A 5-year average of 0.03 and a median of 0.01 in 2022 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2023 and 2025: Equity Ratio slumped 1002.31% in 2023, then jumped 165.55% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.01 in 2022, then plunged by 961.44% to 0.13 in 2023, then plunged by 76.15% to 0.22 in 2024, then jumped by 138.85% to 0.09 in 2025, then declined by 12.8% to 0.08 in 2026.
• Business Quant data shows AKBA's Equity Ratio at 0.08 in Q1 2026, 0.09 in Q4 2025, and 0.11 in Q3 2025.